Topics

Exelixis’ Cabometyx Gets Second Shot at Prostate Cancer

19:00 EST 10 Feb 2020 | BioSpace

In 2014, Exelixis’ Cabometyx (cabozantinib) failed to show survival benefit as a monotherapy in prostate cancer.

Original Article: Exelixis’ Cabometyx Gets Second Shot at Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "Exelixis’ Cabometyx Gets Second Shot at Prostate Cancer"

Quick Search